Because of the therapeutic significance of crizotinib, an ALK tyrosine kinase inhibitor, in ALK rearrangement cases, the differential diagnosis of MEC-like lesions from PMEC and other types of lung adenocarcinoma might be critical. Here, ALK is linked to lung adenocarcinoma.